The U.S. Food and Drug Administration (FDA) has approved Qternmet XR extended-release tablets as an adjunct treatment to diet and exercise in adults with type 2 diabetes. According to a press release from manufacturer AstraZeneca, the oral medicine is a combination of the SGLT2 inhibitor dapagliflozin, the DPP-4 inhibitor saxagliptin and metformin extended-release.
The approval was based on the results of two phase 3 trials evaluating different combinations of dapagliflozin and saxagliptin on a base of metformin over 24 weeks.
Want to learn more about SGLT2 inhibitors, DPP-4 inhibitors and metformin? Read “Diabetes Medicine: SGLT2 Inhibitors,” “Diabetes Medicine: DPP-4 Inhibitors” and “What to Know About Metformin.”
Source URL: https://www.diabetesselfmanagement.com/blog/fda-approves-qternmet-xr-new-type-2-diabetes-combo-pill/
Diane Fennell: Diane Fennell has been an editor at Diabetes Self-Management magazine since 2003. She is currently the Editorial Director. (Diane Fennell is not a medical professional.)
Disclaimer of Medical Advice: Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information, which comes from qualified medical writers, does not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs.
Copyright ©2022 Diabetes Self-Management unless otherwise noted.